Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

NCT01251978 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Choroidal Melanoma

Interventions

DRUG: Ranibizumab 2 mg
DRUG: 0.5 mg Ranibizumab

Sponsor

New England Retina Associates

Collaborators

[object Object]